Shield Therapeutics PLC

STX

Company Profile

  • Business description

    Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

  • Contact

    Northern Design Centre
    Baltic Business Quarter
    Gateshead Quays
    NewcastleNE8 3DF
    GBR

    T: +44 1915118500

    E: [email protected]

    https://www.shieldtherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    73

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,133.106.200.08%
CAC 407,807.0069.36-0.88%
DAX 4022,186.10353.88-1.57%
Dow JONES (US)41,989.9611.80-0.03%
FTSE 1008,577.2257.58-0.67%
HKSE23,202.534.31-0.02%
NASDAQ17,449.89150.600.87%
Nikkei 22535,725.87101.390.28%
NZX 50 Index12,320.197.590.06%
S&P 5005,633.070.000.00%
S&P/ASX 2007,934.509.300.12%
SSE Composite Index3,350.131.690.05%

Market Movers